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tions including IA. Th2 cytokines, i.e. interleukin-4 and -10, have down-
regulatory effects on antifungal phagocytic activity against A. fumigatus.
Neutralization of these cytokines and their immunosuppressive function has
beneficial effects on murine models of IA. The in virro and in vivo
demonstrations of improved outcome of IA by the regulation of these
cytokines offer novel approaches in the management of this serious infection
in immunocompromised patients. Further evaluation of safety and efficacy
of these immunotherapeutic modalities is a new and promising area for
research.
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[fuS3Ol What Is pneumococ:cal resistance? The role of
pharmaco-dynamics in determination of breakpoints
Niels Frimodt-Moller
Dept. o.fClinical Microbiology, Statens Serum Institut, Copenhagen, Denmark.
Penicillin resistance in pneumococci is caused by mutations in the genes
coding for the penicillin-binding proteins (PBP) leading to reduced affinity
for binding of the antibiotics to the PBP's. Additionally changes may take
place in other enzyme systems not related to the PBP's. Increasing number of
mutations in PBP's, or changes due to transformation, leads to increasing
MIC's of beta-lactam antibiotics, while the activities of all other antibiotics
are unaffected. The killing effect of penicillin at similar multiples of the
MIC's is usually the same in susceptible (PSP) and resistant (PRP)strains. If
PBP2x is altered. tolerance towards penicillin may develop. The higher
MIC's have the consequences. that increasing sizes of doses of beta-Iactam
antibiotics are necessary. A clear-cut breakpoint is difficult to define with the
stepwise increase in MIC's. The limit for effect in vivo will be when the
necessary dose to achieve active concentrations at the site ofinfection exceeds
the tolerance of the host. Thus, treating meningitis is problematic due to the
difficulty of beta-lactams to penetrate the blood-brain barrier. Optimal use
of pharmacodynamic principles can, however, reduce the size of the dose
necessary for effect against PRP. It is now clear from various experimental
animal models, that the pharmacokinetic parameters governing the effect in
vivo for penicillins against PSP, i.e. the time> MIC, is the same for PRP's.
Those beta-lactams that have the highest activity against PRP's and that can
achieve high and sustained non-proteinbound concentrations at the site of
infections will therefore have decisive roles in treatment of PRP's. Also,
certain drug combinations can be of benefit against srrains with high MIGs.
ITuS31I Antibiotic treatment Does it make a dierence? The
search for new end points in dinical trials
C. Carbon
Hopital Bichat, Paris, France
Two questions regarding infections in which Streptococcus pneumoniae may
be involved are (i) is antibiotic (AB) treatment always necessary in common
respiratory rract infections (RTis)? (ii) what is the incidence of resistance to
AB on outcome and therapeutic strategies? S. pneumoniM is involved in
different R Tis and may induce severe complications. It is suspected in the
presence of evident clinical symptoms with high fever. Reduced suscept-
ibility to penicillin in R Tis is overcome by increasing amoxicillin doses.
Resistance to macrolides or TMP/SMZ is accompanied by clinical failures.
Clinical trials should only include patients at high risk ofbeing infected by a
pneumococcus and actually needing AB, with discussion of the diagnostic
procedures to get the organism. In phase 2 trials those investigations are
mandatory to establish the intrinsic activity ofthe new drug. In phase 3 trials,
the need for investigations should be based on the current practices for the
given infection. Strong evaluation criteria should be retained to perform an
objective evaluation of the potentialities of the drug. This is easier if only
severe infections are considered. Careful analysis offailures should be made,
along with serum drug levels. Susceptibiliry ofpersisting organisms must be
compared to that of the initial strain. This helps define in vivo breakpoints.
As it is difficult to achieve these goals in clinical trials, in virro and animal
studies on the potential of the new drug to select high level resistant variants
and defmc the limit of the recommended regimens on efficacy are needed.
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ITuS34! Open management of diuse peritonitis
T.Hau
Nordwest-Krankenhaus Sande, Germany
Even though open management of peritonitis is done frequently the
recommendation for its use is based on case series or non-randomized
historic cohort studies. Prospective studies do not show any advantage
over closed techniques. On the basis ofa prospective multicenter study in 334
patients we performed a case controlled study comparing planned re-
laparotomy (PL) to relaparotomy on demand. The matching was based
on the age of the patient, the number of coexisting diseases, the acute
physiology, Score" and the secure source control all ofwhich were found to
be significant prognostic factors. There was no difference in mortality, MOF
and infectious complications due to suture leaIts, recurrent intraabdominal
infections and septicemia were more common after Pi. Some variables in
the PL group, however, indicated that there might be certain subgroups of
patients which may benefit from this procedure and that technical details of
the procedure are important.
In summary, indications for PL should be made with caution. The most
likely patients to benefit from the procedure will be those in whom a proper
peritoneal toilet cannot be performed at the first operation and those who are
in danger of developing an abdominal compartment syndrom.
520 - Management of immunocompromised hosts
with ...
ITuS38I Imaging techniques for early detection and dlerential
diagnosis of pulmonary infiltrates
C. P. Heussel l , H. -U. Kauczor l , A. J. Ullmann2
tDepartment of Radiology; 2111. Medical Department ofMedicine,johlllUres
Gutenberg-University Mainz, Germany
The two major tasks of radiographic imaging in patients with suspected
pneumonia are (1) eady detection including localisation of pulmonary
infiltrates and (2) characterisation of infiltrates for distingnishing between
non-infectious and infectious aetiologies.
Chest radiography (CR) is useful in immunocompetent patients for
detection and follow-up of bacterial pneumonia. However, in immuno-
compromised hosts, during the early phase of infection, CR may fail in
about 50% of the cases to detect an atypical pneumonia. Therefore. more
sensitive methods arc frequently applied. High-resolution computed tomo-
graphy (HRCn, which is the most sensitive technique of computed
tomography to identify infiltrates early on, can safely distinguish between
acute inflammation and non-inflammatory conditions such as scar or
atelectasis. Therefore, CT became the gold standard in chest imaging,
especially in immunocomprornised hosts. CT-scanners are widely available.
The technical requirements and the costs of HRCT and CT are low in
comparison to antibiotics. The radiation dose is about 8-10 fold higher than
in CR (spiral-CT: ~50x). Further techniques are discussed. Pattern recog-
nition in HRCT assists in determining the differential diagnoses. Bacterial.
fungal and viral pneumonia as well as pulmonary congestion, Iymphangio-
sis, graft-versus host disease. graft-rejection and radiation toxicity appear
frequently with specific findings on HRCT.1n comparison to bronchoscopy
and surgery, HRCT is a non-invasive method and offers the clinician
immediately available information for diagnosing a possible underlying
disease. However, this information can be helpful in establishing a diagnosis
but is not always verifiable. Experience, local epidemeology and clinical
information are necessary for the characterisation ofinfiltrates in immuno-
compromised hosts.
ITuS421 Options and limitations of a surgical approach In
patients with invasive pulmonary aspergillosis
M. Tamm
Pneumology, University Hospital Basel, Switzerland; Institute of Re.<piratory
Medicine, University ifSydney, Au.<tralia
Invasive pulmonary aspergillosis (IPA) is a frequent complication in neu-
tropenic patients and associated with a very high mortality. Diagnosis oflPA
is usu:111y based on antibiotic resistant fever combined with localised
infiltrates on CT scan developing in neutropenic patients. Broncboalveolar
